Quantcast
Last updated on April 23, 2014 at 16:09 EDT

Latest VIVUS Inc. Stories

2013-12-17 08:25:59

NEW YORK, December 17, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Today, Analysts' Corner announced new research reports highlighting MiMedx Group, Inc. (NASDAQ: MDXG), NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), VIVUS Inc. (NASDAQ: VVUS), Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK), and GenVec, Inc. (NASDAQ: GNVC). Today's readers may access these reports free of charge - including full price targets, industry...

2013-10-11 08:23:42

- STENDRA Broadens Auxilium's Presence in Men's Health Care With a Projected 2013 Launch into the Multi-Billion Dollar Erectile Dysfunction Market - CHESTERBROOK, Pa., Oct. 11, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL), a specialty biopharmaceutical company, announced today the signing of an agreement with VIVUS, Inc. (Nasdaq: VVUS) providing Auxilium with the exclusive right to market VIVUS's product, STENDRA (avanafil), in the United States and Canada. The...

2013-08-09 08:24:48

Editor Note: For more information about this release, please scroll to bottom NEW YORK, August 9, 2013 /PRNewswire/ -- Today, Investors' Reports announced new research reports highlighting Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), DaVita HealthCare Partners Inc. (NYSE: DVA), Celldex Therapeutics, Inc. (NASDAQ: CLDX), ISIS Pharmaceuticals, Inc. (NASDAQ: ISIS), and VIVUS, Inc. (NASDAQ: VVUS). Today's readers may access these reports free of charge - including full price...

2013-08-09 08:23:48

Editor Note: For more information about this release, please scroll to bottom. LONDON, August 9, 2013 /PRNewswire/ -- On Thursday August 8, 2013, shares in healthcare companies ended on a higher note, tracking gains in the broader market. The major movers in the healthcare sector on Thursday included Vivus Inc. (NASDAQ: VVUS), Sanofi (NYSE: SNY), DENTSPLY International Inc. (NASDAQ: XRAY), and Acura Pharmaceuticals Inc. (NASDAQ: ACUR). AAAResearchReports.com tracked VVUS, SNY,...

2013-07-08 08:27:35

Editor Note: For more information about this release, please scroll to bottom. LONDON, July 8, 2013 /PRNewswire/ -- On Friday, July 5, 2013, shares in healthcare companies ended mostly higher, tracking gains in the broader market. The major movers in the sector included VIVUS Inc. (NASDAQ: VVUS), Sanofi S.A. (ADR) (NYSE: SNY), DENTSPLY International Inc. (NASDAQ: XRAY), and Acura Pharmaceuticals Inc. (NASDAQ: ACUR). AAAResearchReports.com tracked VVUS, SNY, XRAY, and ACUR....

2013-04-16 16:24:13

Retail Availability Expected Within 90 Days MOUNTAIN VIEW, Calif., April 16, 2013 /PRNewswire/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that the U.S. Food and Drug Administration (FDA) has approved its amendment and modification to the Risk Evaluation and Mitigation Strategy (REMS) for Qsymia(® )(phentermine and topiramate extended-release) capsules CIV. The amendment, submitted in October 2012, allows Qsymia( )to be dispensed through certified retail pharmacies, in addition...

2013-04-10 08:30:34

"EXCESS WEIGHT AND YOUR HEALTH" PROGRAM ENCOURAGES PROACTIVE DISCUSSION ABOUT OBESITY MOUNTAIN VIEW, Calif., April 10, 2013 /PRNewswire/ -- A new educational program, Excess Weight and Your Health: A Guide to Effective, Healthy Weight Loss, developed by the Obesity Action Coalition (OAC) and the American College of Physicians (ACP), will be released today at Internal Medicine 2013, the annual scientific meeting of the ACP. The booklet and DVD program, funded by an educational grant...

2013-03-25 08:26:06

10%-15% WEIGHT LOSS AMONG OBESE OR OVERWEIGHT MEDICARE PATIENTS COULD SAVE BILLIONS MOUNTAIN VIEW, Calif., March 25, 2013 /PRNewswire/ -- VIVUS, Inc. (Nasdaq: VVUS) announced today that a new study demonstrates that effective medical treatment providing 10% to 15% weight loss could lead to significant improvements in Medicare spending by reversing or reducing significant health consequences such as type 2 diabetes, hypertension and dyslipidemia in obese or overweight patients. The...

2013-03-07 08:25:00

"Q AND ME" ENCOURAGES LIFESTYLE SKILLS TO AID IN LASTING WEIGHT LOSS MOUNTAIN VIEW, Calif., March 7, 2013 /PRNewswire/ -- VIVUS, Inc. (Nasdaq: VVUS) announced today the launch of the Q and Me(TM) app, a no-cost mobile app available through iTunes and Google Play Store designed to help patients meet their weight loss goals. Q and Me can be used by anyone wanting to develop skills that can lead to lasting weight loss. The Q and Me Patient Support Program (www.QandMEsupport.com) is...

2013-03-05 08:28:26

GET STARTED! AND SAVE NOW! PROGRAMS PROVIDE APPROPRIATE NEW PATIENTS UP TO $150 SAVINGS* MOUNTAIN VIEW, Calif., March 5, 2013 /PRNewswire/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced a new program offering eligible patients a discount on Qsymia(®) (phentermine and topiramate extended-release) capsules CIV for a limited time. The Save Now! Program is available online exclusively at www.qsymia.com and provides patients with the opportunity to pay no more than $75 for 30 days of...